S'abonner

Navigating the landscape of core outcome set development in dermatology - 21/06/19

Doi : 10.1016/j.jaad.2019.03.009 
Cecilia A.C. Prinsen, PhD a, Phyllis I. Spuls, MD, PhD b, Jan Kottner, PhD c, d, , Kim S. Thomas, PhD e, Christian Apfelbacher, PhD f, Joanne R. Chalmers, PhD e, Stefanie Deckert, MPH g, Masutaka Furue, PhD h, Louise Gerbens, PhD b, Jamie Kirkham, PhD i, Eric L. Simpson, PhD j, Murad Alam, MD k, Katrin Balzer, PhD l, Dimitri Beeckman, PhD d, Viktoria Eleftheriadou, PhD e, Khaled Ezzedine, MD m, Sophie E.R. Horbach, PhD n, John R. Ingram, MD, PhD o, Alison M. Layton, MD p, q, Karsten Weller, PhD c, Thomas Wild, MD r, s, t, Albert Wolkerstorfer, PhD b, Hywel C. Williams, DSc e, Jochen Schmitt, MD, MPH g
a Amsterdam UMC, Department of Epidemiology and Biostatistics, Vrije Universiteit University Medical Center, Amsterdam Public Health Research Institute, Amsterdam, the Netherlands 
b Amsterdam UMC, Department of Dermatology, Amsterdam Public Health Research Institute, University of Amsterdam, Amsterdam, the Netherlands 
c Department of Dermatology and Allergy, Charité-Universitätsmedizin Berlin, Berlin, Germany 
d University Centre for Nursing and Midwifery, Department of Public Health and Primary Care, Ghent University, Ghent, Belgium 
e Centre of Evidence-Based Dermatology, University of Nottingham, Nottingham, United Kingdom 
f Institute of Epidemiology and Preventive Medicine, University of Regensburg, Regensburg, Germany 
g Center for Evidence-Based Healthcare, Faculty of Medicine Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany 
h Department of Dermatology, Kyushu University, Fukuoka, Japan 
i Medical Research Council North West Hub for Trials Methodology Research, Department of Biostatistics, University of Liverpool, Liverpool, United Kingdom 
j Department of Dermatology, Oregon Health & Science University, Portland, Oregon 
k Department of Dermatology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois 
l Institute for Social Medicine and Epidemiology, University of Lübeck, Lübeck, Germany 
m Department of Dermatology and Evaluation of Therapeutics, EA7379, Paris-Est University, University Paris Est Créteil, University Hospital Departments Viruses, Immunity, and Cancer, Créteil, France 
n Amsterdam UMC, Department of Plastic, Reconstructive, and Hand Surgery, University of Amsterdam, Amsterdam, the Netherlands 
o Division of Infection and Immunity, University Hospital of Wales, Cardiff University, Cardiff, United Kingdom 
p Hull York Medical School, University of York, York, United Kingdom 
q Harrogate and District National Health Service Foundation Trust, Harrogate, United Kingdom 
r Department of Plastic, Aesthetic, and Hand Surgery, Interdisciplinary Center for Treatment of Chronic Wounds, Dessau Medical Center, Dessau, Germany 
s Department of Dermatology, Venereology, Allergology, and Immunology, Dessau Medical Center, Brandenburg Medical School Theodor Fontane, Neuruppin, Germany 
t Institut of Applied Bio-Sciences and Process Management, University of Applied Science Anhalt, Koethen, Germany 

Reprint requests: Jan Kottner, PhD, Charité-Universitätsmedizin Berlin, Department of Dermatology and Allergy, Charitéplatz 1, 10117 Berlin, Germany.Charité-Universitätsmedizin BerlinDepartment of Dermatology and AllergyCharitéplatz 1Berlin10117Germany

Abstract

The development of core outcome sets (COSs; ie, a minimum set of core outcomes that should be measured and reported in all trials or in clinical practice for a specific condition) in dermatology is increasing in pace. A total of 44 dermatology-related COS projects have been registered in the online Core Outcome Measures in Effectiveness Trials database (search) and include studies on 26 different skin diseases. With the increasing number of COSs in dermatology, care is needed to ensure the delivery of high-quality COSs that meet quality standards when using state-of-the-art methods. In 2015, the Cochrane Skin–Core Outcome Set Initiative (CS-COUSIN) was established. CS-COUSIN is an international, multidisciplinary working group aiming to improve the development and implementation of COSs in dermatology. CS-COUSIN has developed guidance on how to develop high-quality COSs for skin diseases and supports dermatology-specific COS initiatives. Currently, 17 COS development groups are affiliated with CS-COUSIN and following standardized COS development processes. To ensure successful uptake of COSs in dermatology, researchers, clinicians, systematic reviewers, guideline developers, and other stakeholders should use existing COSs in their work.

Le texte complet de cet article est disponible en PDF.

Key words : clinical trials, Cochrane Skin, core outcome set, CS-COUSIN, dermatology, development, implementation

Abbreviations used : COMET, COS, COSMIN, CS-COUSIN, HOME, OMERACT


Plan


 Funding sources: None.
 Conflicts of interest: All authors are members of the Cochrane Skin–Core Outcome Set Initiative.


© 2019  American Academy of Dermatology, Inc. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 81 - N° 1

P. 297-305 - juillet 2019 Retour au numéro
Article précédent Article précédent
  • Future considerations for clinical dermatology in the setting of 21st century American policy reform: Corporatization and the rise of private equity in dermatology
  • Sailesh Konda, Joseph Francis, Kiran Motaparthi, Jane M. Grant-Kels, Group for Research of Corporatization and Private Equity in Dermatology
| Article suivant Article suivant
  • Beyond JAAD July 2019: Articles of interest to dermatologists from the nondermatologic literature
  • Andrew Bronin, Robert Phelps, Robert Sidbury

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.